Stock Fundamentals

Company Information

Company Name
Aligos Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US01626L2043
CIK: 0001799448
CUSIP: 01626L105
Currency: USD
Full Time Employees: 82
Phone: 800 466 6059
Fiscal Year End: December
IPO Date: Oct 16, 2020
Description:

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Address:

One Corporate Drive, South San Francisco, CA, United States, 94080

Directors & Officers

Name Title Year Born
Dr. Lawrence M. Blatt MBA, Ph.D. CEO, President & Chairman of the Board 1962
Dr. Julian A. Symons DPHIL Executive VP & Chief Scientific Officer 1962
Mr. Nikhil Aneja Principal Accounting Officer 1977
Ms. Laura Kavanaugh VP & Head of Legal NA
Ms. Kristina Engeseth M.B.A. Senior VP and Head of People & Culture NA
Dr. Sushmita M. Chanda DABT, Ph.D. Executive Vice President & Chief Development Officer 1967
Dr. David B. Smith Ph.D. Executive VP & Head of Chemical Operations NA
Dr. Tse-I Lin Ph.D. Senior VP of Early Compound Development & Belgian Site Head NA
Dr. Kieron Wesson Ph.D. Vice President & Head of Chemistry Manufacturing Controls NA
Dr. Ramon Polo M.B.A., Ph.D., Pharm.D. Senior VP & Head of Global Regulatory Affairs NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Oct 25, 2023 Carole Nuechterlein N/A Purchase 317.34K $19.00 $6.03M

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Deep Track Capital, LP 444.11K Mar 31, 2026 7.18% $0.05 0.00%
Alyeska Investment Group, L.P. 412.00K Mar 31, 2026 6.66% $0.01 0.00%
Sio Capital Management, LLC 327.24K Mar 31, 2026 5.29% $0.35 -2.59%
Marshall Wace Asset Management Ltd 267.14K Mar 31, 2026 4.32% $0.00 -0.57%
Bank of America Corp 229.75K Mar 31, 2026 3.71% $0.00 1,652.78%
Vanguard Group Inc 200.40K Dec 31, 2025 3.24% $0.00 16.72%
Vanguard Capital Management, LLC 178.26K Mar 31, 2026 2.88% $0.00 0.00%
Woodline Partners LP 177.36K Mar 31, 2026 2.87% $0.01 -38.66%
SummitTX Capital, L.P 148.80K Mar 31, 2026 2.40% $0.03 6.72%
Renaissance Technologies Corp 100.45K Mar 31, 2026 1.62% $0.00 17.56%
Baker Bros Advisors LP 83.06K Mar 31, 2026 1.34% $0.00 0.00%
Hillhouse Capital Advisors, Ltd. 76.25K Dec 31, 2025 1.23% $0.02 0.00%
Citadel Advisors Llc 54.31K Mar 31, 2026 0.88% $0.00 4.78%
LPL Financial Corp 51.50K Mar 31, 2026 0.83% $0.00 -21.97%
Geode Capital Management, LLC 49.98K Mar 31, 2026 0.81% $0.00 4.68%
UBS Group AG 37.06K Mar 31, 2026 0.60% $0.00 10,081.59%
Vanguard Fiduciary Trust Co 28.44K Mar 31, 2026 0.46% $0.00 0.00%
Two Sigma Investments LLC 23.09K Mar 31, 2026 0.37% $0.00 -71.37%
Verition Fund Managegment, LLC 18.89K Mar 31, 2026 0.31% $0.00 -73.49%
XTX Topco Ltd 14.20K Mar 31, 2026 0.23% $0.00 -38.42%

Shares Statistics

Shares Outstanding: 5.39M
Shares Float: 3.64M
% Insiders: 1,036.60%
% Institutions: 5,508.30%
Short % Float: 10.99%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 126.97K 2.05% ▲ 0.00% Apr 30, 2026
2 Vanguard Institutional Extnd Mkt Idx Tr 46.95K 0.76% ▲ 0.00% Apr 30, 2026
3 Fidelity Extended Market Index 24.81K 0.40% ▼ 0.37% Apr 30, 2026
4 Fidelity Total Market Index 7.55K 0.12% ▲ 0.00% Apr 30, 2026
5 Spartan Extended Market Index Pool F 6.19K 0.10% ▲ 1.49% Apr 30, 2026
6 Extended Equity Market Fund E 6.18K 0.10% ▲ 0.00% Dec 31, 2025
7 Blackrock Extended Mkt Fund CF 6.18K 0.10% ▲ 0.00% Apr 30, 2026
8 Extended Equity Market Fund B 6.18K 0.10% ▲ 0.00% Dec 31, 2025
9 Fidelity Series Total Market Index 6.14K 0.10% ▲ 0.00% Apr 30, 2026
10 BlackRock Extended Equity Market Fund K 5.26K 0.09% ▼ 0.74% Mar 31, 2026

Valuation Metrics

Enterprise Value: $-17.88M
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

Market Cap: $32.67M
EBITDA: $-94.59M
Book Value: $5.14
Earnings/Share: $-9.78
Profit Margin: 0.00%
Operating Margin: -951.56%
ROA (TTM): -55.56%
ROE (TTM): -121.86%
Revenue (TTM): $4.71M
Revenue/Share (TTM): $0.45
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 810.00%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 3.90x 0.07x 0.40x N/A -0.16x
2024-12-31 2.86x -0.12x 1.41x N/A -0.03x
2023-12-31 5.90x 0.04x 0.39x N/A -0.04x
2022-12-31 4.03x 0.03x 0.29x -59.50x -0.03x
2021-12-31 5.25x 0.02x 0.22x -972.13x -0.02x
2020-12-31 8.26x 0.01x 0.17x -9.28x -0.03x
2019-12-31 8.70x -0.04x 1.44x -28.99x -0.05x
2018-12-31 12.33x -0.09x 1.13x N/A -0.10x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about ALGS.US!